Yinnuo Pharmaceutical-B (02591) signed a licensing agreement with Arcera for the development and commercialization of drugs containing Efsubaglutide Alfa

Zhitongcaijing · 2d ago

According to Zhitong Finance App, Yinnuo Pharmaceutical-B (02591) announced that on November 19, 2026, Hong Kong Yinnuo Pharmaceutical Holdings Limited (Hong Kong Yinnuo), an indirect wholly-owned subsidiary of the Company, entered into a licensing agreement with Arcera Life Sciences LTD (Arcera), a member company of the global pharmaceutical group Arcera Life Sciences (Arcera) (as licensee).

Yinnuo Hong Kong granted Arcera an exclusive license for an initial period of 15 years to develop (only to the extent required to obtain and maintain regulatory approval) and commercialize drugs containing Efsubaglutide Alfa for human therapeutic use in a number of countries in Africa, Latin America, the Middle East and Eastern Europe.

In exchange for granting such licenses and rights under the license agreement, Hong Kong Yinnuo is entitled to collect a total down payment of up to 38 million US dollars and recent milestone payments (including an unrefundable down payment of 15 million US dollars), as well as sales milestone payments and tiered royalties of up to a double digit percentage rate calculated based on the total annual net sales of the product within the region. The total potential deal is worth over $1 billion.

The signing of a license agreement can help Arcera's commercial network in emerging markets accelerate Efsubaglutide Alfa's international expansion and enhance its commercial value. The Board believes that this move is in the overall best interests of the Company and its shareholders.